Remimazolam
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Remimazolam: From Procedural Sedation and General Anaesthesia to Insomnia
One-Sentence Summary
Remimazolam is an ultra-short-acting intravenous benzodiazepine, originally used for procedural sedation and for induction and maintenance of general anaesthesia in adults. The TxGNN model predicts it may be effective for insomnia, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on model output and class-level mechanistic reasoning alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Procedural sedation in adults; intravenous induction and maintenance of general anaesthesia (50 mg) in adults |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| EU Market Status | Cancelled only (no currently valid authorization) |
| Number of Authorizations | 1 (cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on class knowledge, remimazolam is a benzodiazepine that acts as a positive allosteric modulator of GABA-A receptors. This is the same mechanism that underlies established benzodiazepine hypnotics, which makes the high TxGNN score biologically plausible.
Sedation and insomnia treatment both rely on enhancing inhibitory GABAergic signalling in the brain. In that sense, the original indication (sedation and anaesthesia) and the predicted indication (insomnia) are pharmacologically related.
However, the drug’s pharmacokinetics work against this use. It is given intravenously and is rapidly broken down by tissue esterases, so its duration of action is very short. That profile suits procedural sedation but not sleep maintenance. The data compiled for this report describe no oral or other chronic-use formulation. The link is therefore based on class knowledge rather than on a documented mechanism record.
A second predicted indication, alcohol withdrawal delirium (score 99.30%), is also listed. Benzodiazepines are the standard of care for alcohol withdrawal, and remimazolam’s rapid onset and offset could in theory allow fast titration in intensive care. This remains a hypothesis with no supporting trials or literature. It would need to be weighed against established agents such as diazepam, lorazepam and phenobarbital, and an ultra-short-acting agent may require continuous infusion to provide the sustained dosing that resistant withdrawal needs.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| EMEA/H/C/005246 (cancelled) | Byfavo | Not specified | Remimazolam is indicated in adults for procedural sedation. Remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general… |
Safety Considerations
- Drug Interactions: 54 interactions were identified. Examples of the Major-level interactions are:
- Morphine, including liposomal morphine
- Codeine
- Hydrocodone
These are consistent with additive central nervous system and respiratory depression when combined with opioids.
- Moderate-level interactions include:
- Ethanol
- Promethazine
- Chlorpheniramine
- Cetirizine
- Metoclopramide
- Bupropion
- Dronabinol
- Nabilone
- Opium
- Lidocaine
- Disulfiram
- Dextromethorphan
For warnings and contraindications, please refer to the SmPC.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high and the GABA-A mechanism is plausible for a hypnotic effect. However, there are no clinical trials or publications for insomnia, and the intravenous, ultra-short-acting profile is poorly matched to sleep maintenance. The only EU authorization is also cancelled.
To proceed, the following is needed:
- Warnings and contraindications from the SmPC, which are currently missing and block safety screening
- Mechanism of action data to support the mechanistic-link analysis
- Evidence that a suitable formulation or dosing route exists for chronic or nightly use
- Preclinical or early clinical data for insomnia, and a comparison with established hypnotics
- A separate assessment of alcohol withdrawal delirium against standard-of-care benzodiazepines and phenobarbital
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.